Indaptus Therapeutics

Indaptus Therapeutics is a clinical-stage biotechnology company developing immunotherapy candidates for cancer and viral infections based on its Decoy bacterial platform. Its lead candidate, Decoy20, uses attenuated and killed non-pathogenic Gram-negative bacteria designed to activate innate and adaptive immune responses, with a prior focus on solid tumors (lymphoma, hepatocellular, colorectal, and pancreatic) and chronic infections. In 2026 the company discontinued enrollment in its Decoy20 clinical program, reduced R&D spending sharply, and began evaluating strategic alternatives including research collaborations and potential business combinations while pursuing a research collaboration in neurological disorders and sleep.